StreetInsider.com News Articles

Cullinan Therapeutics to host investor event after Phase 3 lung cancer trial data

Thu, 10 Sep 2026 13:00:13 -0400

Cullinan Therapeutics, Inc. (Nasdaq: CGEM) will host a virtual event for analysts and institutional investors on September 14, 2026, at 8:00 a.m. ET to discuss results from a planned interim analysis of its Phase 3 REZILIENT3 trial.

The trial evaluated zipalertinib combined with chemotherapy as a first-line treatment for patients with EGFR exon 20 insertion mutation-positive non-small cell lung cancer (NSCLC). According to the company, the trial met its primary endpoint of progression-free survival at the planned interim analysis.

The data are scheduled to be presented in Presidential Symposium 2 on September 13, 2026, at the International Association for the Study of

Cullinan Therapeutics to Host Virtual Analyst and Investor Event to Showcase Zipalertinib Plus Chemotherapy Phase 3 REZILIENT3 Data Presented at the IASLC 2026 World Conference on Lung Cancer

Thu, 10 Sep 2026 13:00:00 -0400

Results from the planned interim analysis of the Phase 3 REZILIENT3 trial of zipalertinib plus chemotherapy in first-line EGFR exon 20 insertion mutation NSCLC to be presented in Presidential Symposium 2 on Sunday, September 13, 2026

Company to host a virtual event on Monday, September 14, 2026, at 8:00 a.m. ET

CAMBRIDGE, Mass., Sept. 10, 2026 (GLOBE NEWSWIRE) -- Cullinan Therapeutics, Inc. (Nasdaq: CGEM), a clinical-stage biopharmaceutical company accelerating potential first- or best-in-class, disease-modifying T cell engagers in autoimmune diseases and cancer, today announced that it will host a virtual event

Cullinan Therapeutics to Host Virtual Analyst and Investor Event to Showcase Zipalertinib Plus Chemotherapy Phase 3 REZILIENT3 Data Presented at the IASLC 2026 World Conference on Lung Cancer

Thu, 10 Sep 2026 13:00:00 -0400

Company to host a virtual event on Monday, September 14, 2026, at 8:00 a.m. ET

Form 4 Cullinan Therapeutics, For: Sep 08 Filed by: Michaelson Jennifer

Thu, 10 Sep 2026 09:23:00 -0400

si-local-file:///var/storage/secattach/20260910/27046343.html

TD Cowen Assumes Cullinan Oncology Inc. (CGEM) at Buy

Sat, 22 Aug 2026 07:55:05 -0400

TD Cowen analyst Phil Nadeau assumes coverage on Cullinan Oncology Inc. (NASDAQ: CGEM) with a Buy rating.

For an analyst ratings summary and ratings history on Cullinan Oncology Inc. click here. For more ratings news on Cullinan Oncology Inc. click here.

Shares of Cullinan Oncology Inc. closed at $21.68 yesterday.

Zipalertinib trial data to be presented at IASLC lung cancer conference

Wed, 19 Aug 2026 12:03:15 -0400

Taiho Oncology, Inc. and Cullinan Therapeutics, Inc. (Nasdaq: CGEM) announced that interim analysis results from the Phase 3 REZILIENT3 trial have been selected for presentation at the International Association for the Study of Lung Cancer's 2026 World Conference on Lung Cancer, scheduled for September 12-15, 2026, in Seoul, South Korea.

The data will be presented during Presidential Symposium 2 on September 14, 2026. According to the companies, the trial met its primary endpoint of progression-free survival in the first-line treatment of patients with EGFR exon 20 insertion mutation-positive non-small cell lung cancer (NSCLC).

The REZILIENT3 trial is a multicenter, randomized, controlled, open-label

Zipalertinib trial data to be presented at IASLC lung cancer conference

Wed, 19 Aug 2026 12:03:15 -0400

The REZILIENT3 trial is a multicenter, randomized, controlled, open-label

Zipalertinib trial data to be presented at IASLC lung cancer conference

Wed, 19 Aug 2026 12:03:15 -0400

The REZILIENT3 trial is a multicenter, randomized, controlled, open-label

Zipalertinib trial data to be presented at IASLC lung cancer conference

Wed, 19 Aug 2026 12:03:15 -0400

The REZILIENT3 trial is a multicenter, randomized, controlled, open-label

Zipalertinib Plus Chemotherapy First-Line Phase 3 REZILIENT3 Trial Data Selected for Presidential Symposium Presentation at the IASLC 2026 World Conference on Lung Cancer